Fiercely Focused
On Treatments

Voluntary Withdrawal of UKONIQ® (umbralisib)

TG Therapeutics has voluntarily withdrawn UKONIQ® from sale for the approved indications of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for the treatment of adult patients with follicular lymphoma (FL) who have received at least three prior systemic therapies.

  • For the Company’s press release with more information regarding the withdrawal of UKONIQ click here
  • For important information for healthcare professionals regarding the withdrawal of UKONIQ click here
  • For the U.S. prescribing information for UKONIQ click here
  • For any questions related to the information on this page please contact: 1-877-848-9462